Evidence map›Paper›PMID 30073610›Full record

ArticleInternational journal of clinical pharmacy2018

The role and strategy of ISoP in global pharmacovigilance.

Sten Olsson, Mira Harrison-Woolrych

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Overview of this issue: pharmacovigilance, what is new?International journal of clinical pharmacy · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sten OlssonThe International Society of Pharmacovigilance, 140 Emanuel Road, London, SW12 0HS, UK. president@isoponline.org.ORCID http://orcid.org/0000-0002-6078-0649
Mira Harrison-WoolrychThe International Society of Pharmacovigilance, 140 Emanuel Road, London, SW12 0HS, UK.
International Society of Nephrology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Applying the WHO definition of pharmacovigilance, the International Society of Pharmacovigilance, (ISoP) is concerned with all aspects of medicine safety. The safety of patients exposed to medicines depends on a wide variety of factors, where the understanding of each factor is associated with its own professional competence and skillset. For pharmacovigilance systems to work efficiently, a broad understanding of the necessary contribution of each of the different scientific competence areas and professional skills is required. ISoP is an independent, not-for-profit international professional organization, concerned with the best interest of patients exposed to pharmaceutical interventions in all healthcare systems in the world. ISoP offers an open platform for professionals from around the world with different expertise and skillsets, to network and exchange information and knowledge in a friendly environment. The society wishes to become a stronger global voice, speaking up in favour of patient safety and to be at the frontline of the global patient safety movement.

Indexed as

Global HealthPharmacovigilanceAdverse Drug Reaction Reporting SystemsCooperative BehaviorDrug-Related Side Effects and Adverse ReactionsHumansInterdisciplinary CommunicationOrganizations, NonprofitPatient SafetyRisk AssessmentRisk FactorsSocieties, MedicalDrug safetyInternational associationNon-profitPatient safetyPharmacovigilance

Identifiers

PMID30073610
OpenAlexW2887174093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.